InVivoMAb anti-mouse 4-1BB (CD137)

Qi X, Li F, Wu Y, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019,10(1):2141. doi: 10.1038/s41467-019-10088-1

Giardino Torchia ML, Munitic I, Castro E, et al. c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival. Eur J Immunol. 2015,45(9):2672-82. doi: 10.1002/eji.201445342

Kobayashi T, Doff BL, Rearden RC, et al. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology. 2015,4(3):e990793.

Guillerey C, Ferrari de Andrade L, Vuckovic S, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015,125(5):2077-89. doi: 10.1172/JCI77181

Tewalt EF, Cohen JN, Rouhani SJ, et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood. 2012,120(24):4772-82. doi: 10.1182/blood-2012-04-427013

Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012,72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210

Vezys V, Penaloza-MacMaster P, Barber DL, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol. 2011,187(4):1634-42. doi: 10.4049/jimmunol.1100077